<DOC>
	<DOCNO>NCT00604279</DOCNO>
	<brief_summary>The purpose study compare efficacy paliperidone palmitate risperidone long act injection ( LAI ) participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) along safety tolerability .</brief_summary>
	<brief_title>A Comparative Study Paliperidone Palmitate Risperidone Long Acting Injection ( LAI ) Participants With Schizophrenia</brief_title>
	<detailed_description>This randomize ( assigned chance ) , open-label ( people know identity intervention ) , active-controlled , parallel-group ( medical research study compare response two group participant receive different treatment ) , multicenter ( one hospital medical school team work medical research study ) comparative study participant schizophrenia . This study comprise screen period 7 day 13-week open-label treatment period . Paliperidone palmitate administer intramuscular injection ( injection substance muscle ) 150 milligram equivalent ( mg eq . ) baseline , 100 mg eq . Day 8 , flexible dose Day 36 ( 50 100 mg eq . ) Day 64 ( 50 , 100 150 mg eq . ) depend investigator 's discretion . Risperidone LAI administer dose 25 mg Day 8 Day 22 , flexible dose Day 36 ( 25 37.5 mg ) Day 64 ( 25 , 37.5 , 50 mg ) . Dose Day 50 Day 36 dose Day 78 Day 64 . Participants receive oral risperidone tablet ( 1 6 mg/day ) first 4 week open-label treatment period . Each participant may receive oral risperidone tablet ( 1 2 mg daily ) 3 week Day 36 Day 64 dose risperidone LAI increase Day 36 Day 64 . Efficacy primarily assess use Positive Negative Syndrome Scale ( PANSS ) . Participants ' safety also assess .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Participants meet diagnostic criterion schizophrenia accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) ( disorganize type [ 295.10 ] , catatonic type [ 295.20 ] , paranoid type [ 295.30 ] , residual type [ 295.60 ] , undifferentiated type [ 295.90 ] ) least 1 year screen prior medical record , write documentation , verbal information obtain previous psychiatric provider obtain investigator must consistent diagnosis schizophrenia A total Positive Negative Syndrome Scale ( PANSS ) score 60 120 , inclusive , screen baseline Body mass index ( BMI ) equal great 17.0 kilogram per meter square ( kg/m^2 ) Female participant must postmenopausal least 2 year , surgically sterile , abstinent , , sexually active , practice effective method birth control study entry throughout study Be capable selfadministering study medication ( apply oral supplementation ) assistance study medication administration consistently available throughout first 4 week study A primary , active DSMIV diagnosis Axis I schizophrenia A decrease least 25 percent total PANSS score screen baseline Participants previously participate study A DSMIV diagnosis active substance dependence within 3 month screen ( nicotine caffeine exclusionary ) History treatment resistance define failure respond 2 adequate treatment different antipsychotic medication ( adequate treatment define minimum 6 week maximum tolerated dosage )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperidone long act injection</keyword>
	<keyword>R092670</keyword>
</DOC>